VBI Vaccines Inc.

VBI Vaccines — Corporate Update (April 2019)

13 slides from VBI Vaccines's corporate update, Apr 25, 2019

  1. Slide 1: Pipeline Update Conference Call

    wiltlli > VBI VACCINES M, Pipeline Update Conference Call NASDAQ: VBIV APRIL 25 2019

  2. Slide 2: Forward-Looking Statements

    OOOO eee Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking i

  3. Slide 3: Agenda

    OOO eee Agenda 1. UPDATE ON VBI-1901 : GBM IMMUNO-THERAPEUTIC 2. UPDATE ON VBI-2601 : HEPATITIS B IMMUNO-THERAPEUTIC 3. UPDATE ON SCI-B-VAC® : TRIVALENT HEPATITIS B VACCINE 4. SUMMARY OF NEAR-TERM MILESTONES 5. Q&A NASDAQ: VBIV 3

  4. Slide 4: GBM Phase I/IIa Clinical Study Design

    OOO eee GBM Phase I/Ila Clinical Study Design TWO-PART, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF VBI-1901 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) PARTA: PART B: Dose-Escalation Phase Patient population : Recurrent GBM (any # of recurrences) Dose(s) : o Low-—0.4pg of pp65 > 6 subjects

  5. Slide 5: Impact of Vaccination on CMV-Specific Immunity

    Impact of Vaccination on CMV-Specific Immunity SNO 2018 DATA — PATIENT-SPECIFIC DATA OF RESPONDERS Low-Dose Cohort (0.41 of pp65) Intermediate-Dose Cohort (2.0 of pp65) Subject 01-003 Subject 01-007 Subject 01-012 Subject 03-002 2 recurrences 3 recurrences 2 recurrences 1 recurrence CMV gB Antibody

  6. Slide 6: Upcoming Program Milestones: VBI-1901 (GBM)

    Upcoming Program Milestones : VBI-1901 (GBM) PART A: Dose-Escalation Phase * June 2019 — ASCO Poster Presentation : o Expanded immunologic data from low-, intermediate-, and high-dose cohorts © Correlation between vaccine and tumor/clinical responses, as assessed by MRI and survival data PART B : Ex

  7. Slide 7: Functional Cure Combination for Hepatitis B

    Functional Cure Combination for Hepatitis B Scientific consensus is that a functional cure is within reach, but will likely be achieved through a combination approach A functional cure will likely require the achievement of the below: 1. Drive down hepatitis B virus (HBV) DNA 2. Drive down immuno-su

  8. Slide 8: VBI-2601 Well Positioned as an Immuno-Therapeutic Component of a Functional Cure

    VBI-2601 Well Positioned as an Immuno-Therapeutic Component of a Functional Cure for Hepatitis B VBI-2601 is designed to impact circulating virus (via anti-S immunity — step 7), viral entry (via pre-S1 immunity — step 1), and infected hepatocytes (via T-cell immunity — step 8) Current NUCs & next-ge

  9. Slide 9: Program Milestones: VBI-2601 (Tx HBV)

    OOOO eee Program Milestones : VBI-2601 (Tx HBV) & vecenper 2018 : License and collaboration agreement announced with Brii Biosciences for up to $129M + royalties to develop a functional cure for hepatitis B 4 aes 2019 : Initiation of pre-clinical studies UO) Around year-end 2019 : Expected start of

  10. Slide 10: Sci-B-Vac: Two Ongoing Phase III Studies to Support Licensure

    Sci-B-Vac®: Two Ongoing Phase III Studies to Support Licensure in U.S., Europe, and Canada PROTECT CONSTANT Phase Ill Study 2-arm safety and immunogenicity study N size ~1,500 ~2,900 Control Vaccine Engerix-B® (GSK) Engerix-B® (GSK) Based on seroprotection rates (SPR): Consistency of immune response

  11. Slide 11: Sci-B-Vac: High & Rapid SPR in Adults

    Sci-B-Vac®: High & Rapid SPR in Adults EASL 2019 POSTER DATA Three previously-conducted clinical studies in adults aged 18-45 years Seroprotection Rates (SPR) and anti-HBs titers (GMC) Month 2 Month 6 Month7 Month 12 SPR% (GMC) SPR% (GMC) SPR% (GMC) SPR% (GMC) Studies Post-2"4 Dose Post-2"4 Dose Pos

  12. Slide 12: Summary

    Summary NOTABLE CATALYSTS THROUGH 2019 YEAR-END: @ VBI-1901: GBM (Immuno-Oncology) June 2019, ASCO Poster Presentation — Expanded immunologic data, and correlation between vaccine and tumor/clinical responses expected in all dose cohorts in Part A of the ongoing Phase I/Ila study H2 2019 — Initial i

  13. Slide 13: VBI Vaccines Inc. contact

    VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com

VBI Vaccines — Corporate Update (April 2019) on 6ix